Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

When scientists develop new molecules—whether for the purposes of agriculture, species control, or life-savings drugs—it’s ...

In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

Taiwan Semiconductor Manufacturing is seeking to cut some lurid allegations from a job-discrimination lawsuit, claiming they ...

Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

A virus originally found in animals, mpox -- which causes the disease of the same name -- is now circulating in humans. Since 2022, it has been the cause of major epidemics spreading outside endemic ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...